[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Le Voyer et al., 2023 - Google Patents

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

Le Voyer et al., 2023

View HTML
Document ID
15624023939567926445
Author
Le Voyer T
Parent A
Liu X
Cederholm A
Gervais A
Rosain J
Nguyen T
Perez Lorenzo M
Rackaityte E
Rinchai D
Zhang P
Bizien L
Hancioglu G
Ghillani-Dalbin P
Charuel J
Philippot Q
Gueye M
Maglorius Renkilaraj M
Ogishi M
Soudée C
Migaud M
Rozenberg F
Momenilandi M
Riller Q
Imberti L
Delmonte O
Müller G
Keller B
Orrego J
Franco Gallego W
Rubin T
Emiroglu M
Parvaneh N
Eriksson D
Aranda-Guillen M
Berrios D
Vong L
Katelaris C
Mustillo P
Raedler J
Bohlen J
Bengi Celik J
Astudillo C
Winter S
NF-κB Consortium Boisson-Dupuis Stéphanie 1 2 9 Oksenhendler Eric 73 Okada Satoshi 109 Caluseriu Oana 110 Ursini Mathilde Valeria 111 Ballot Eric 112 Lafarge Geoffroy 11 87 Freiberger Tomas 66 Arango-Franco Carlos A. 1 2 Levy Romain 1 2 52 COVID Human Genetic Effort Aiuti Alessandro 113 Al-Muhsen Saleh 114 Al-Mulla Fahd 115 Andreakos Evangelos 116 Arias Andrés A. 9 117 118 Feldman Hagit Baris 119 Bastard Paul 1 2 9 52 Bondarenko Anastasia 120 Borghesi Alessandro 121 Bousfiha Ahmed A. 122 Brodin Petter 123 Bryceson Yenan 124 Casari Giorgio 125 Christodoulou John 126 Colobran Roger 127 Condino-Neto Antonio 128 Fellay Jacques 129 130 Flores Carlos 131 132 133 Franco José Luis 19 Haerynck Filomeen 134 Halwani Rabih 114 135 Hammarström Lennart 39 40 Heath James R. 136 Hsieh Elena WY 137 Itan Yuval 138 139 Kaja Elżbieta 140 Kisand Kai 141 Ku Cheng-Lung 142 Ling Yun 143 Lau Yu-Lung 144 Mansouri Davood 145 Meyts Isabelle 146 147 Milner Joshua D. 148 Mogensen Trine H. 149 Novelli Antonio 150 Novelli Giuseppe 151 Okamoto Keisuke 152 Ozcelik Tayfun 153 de Diego Rebeca Perez 154 Perez-Tur Jordi 155 Perlin David S. 156 Prando Carolina 157 Pujol Aurora 158 159 160 Quintana-Murci Lluis 161 Renia Laurent 162 163 Resnick Igor 164 Rodríguez-Gallego Carlos 133 165 Sancho-Shimizu Vanessa 166 167 Sediva Anna 55 Seppänen Mikko RJ 168 169 Shahrooei Mohammed 78 Shcherbina Anna 170 Palacín Pere Soler 171 Pesole Graziano 172 Spaan András N. 9 Su Helen C. 15 41 Tancevski Ivan 173 Tayoun Ahmad Abou 174 Amara Ali 175 Gorochov Guy 176 Temel Şehime Gülsün 177 178 Thorball Christian 130 Tiberghien Pierre 179 Trouillet-Assant Sophie 104 Turvey Stuart 180 Uddin KM Furkan 181 Uddin Mohammed J. 182 183 van de Beek Diederik 184 Vidigal Mateus 185 Vinh Donald C. 186 187 von Bernuth Horst 188 189 190 Wauters Joost 191 Zatz Mayana 185 Zhang Shen-Ying 1 2 9 Ng Lisa FP 162 163
Publication year
Publication venue
Nature

External Links

Snippet

Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs),, conferring a predisposition to life-threatening COVID-19 pneumonia …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Le Voyer et al. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
Lam et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function
Castro et al. NCKAP1L defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation
Kinloch et al. In situ humoral immunity to vimentin in HLA-DRB1* 03+ patients with pulmonary sarcoidosis
Benjamin Larman et al. Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis
Masters et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation
Linka et al. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases
Cvetkovic-Lopes et al. Elevated Tribbles homolog 2–specific antibody levels in narcolepsy patients
Baek et al. Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss
Zou et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis
Chapman et al. Functional genomics and gene-environment interaction highlight the complexity of congenital heart disease caused by Notch pathway variants
Frémond et al. COPA syndrome, 5 years after: Where are we?
ES2818823T3 (en) PML risk assessment method
Chiang et al. Differences in granule morphology yet equally impaired exocytosis among cytotoxic T cells and NK cells from Chediak–Higashi syndrome patients
EP1354199A2 (en) Diagnosis and treatment of multiple sclerosis
Ali et al. Endoplasmic reticulum quality control is involved in the mechanism of endoglin-mediated hereditary haemorrhagic telangiectasia
JPWO2012039161A1 (en) New vasculitis test method and test reagent
Csuka et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein–Barr nuclear antigen 1 and its aa35–58 or aa398–404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis
Hapnes et al. Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups
Standing et al. TRAP1 chaperone protein mutations and autoinflammation
Yogeshwar et al. HLA-DQB1* 05 subtypes and not DRB1* 10: 01 mediates risk in anti-IgLON5 disease
David et al. Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus
Marquardsen et al. Detection of Sp110 by flow cytometry and application to screening patients for veno-occlusive disease with immunodeficiency
Zhang et al. Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy
US7709215B2 (en) Method for diagnosing and treating acute joint injury